<DOC>
	<DOCNO>NCT00811460</DOCNO>
	<brief_summary>This crossover study assess effect 2 dos Taspoglutide first- second-phase insulin secretion patient type 2 diabetes . Patients receive continuous subcutaneous infusion ) Immediate Release Formulation ( IRF ) Taspoglutide 300 micrograms/day 2 day follow Taspoglutide 800 micrograms/day 2 day b ) saline placebo 2+2 day . After washout period 10-15 day , patient crossed-over treatment ; receive Taspoglutide period 1 receive placebo period 2 , vice versa . On day 2 4 period , insulin secretion pattern assess . The anticipated time study treatment &lt; 3 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Taspoglutide Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>adult patient , 1865 year age ; type 2 diabetes mellitus ; treat diet exercise alone , combination stable metformin least 3 month prior screen . type 1 diabetes mellitus ; type 2 diabetes duration &lt; 3 month ; treatment oral antihyperglycemic medication metformin monotherapy last 3 month ; treatment insulin &gt; 7 day within 6 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>